Medicaid beneficiaries had a higher risk of death than commercially-insured patients, but the risk of death decreased if Medicaid beneficiaries underwent biomarker testing.
Immunotherapy prolonged survival compared with platinum chemotherapy.
Combining either oleclumab or monalizumab with durvalumab provided a progression-free survival benefit over durvalumab alone.
The 2-year overall survival rate was 32.5%.
Segmentectomy prolonged 5-year overall survival in a phase 3 trial.
Having a high blood tumor mutational burden was associated with a significant improvement in response and a trend toward improvement in survival outcomes.
The mean heart dose decreased from 12.2 Gy before the intervention to 10.4 Gy after.
Canakinumab did not improve response rates, progression-free survival, or overall survival.
Adding nivolumab to chemotherapy improved the pathologic complete response rate and prolonged event-free survival.
Health-related quality of life was generally superior with immunotherapy plus chemotherapy vs chemotherapy alone.
